Streetbeat News

PBM

Psyence Biomedical Ltd. Common Shares

https://www.psyence.com

Industry

Biotechnology

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Psyence Biomedical and Optimi Health have signed a non-binding letter of intent to collaborate on global psilocybin drug development. Optimi Health will become the exclusive supplier of GMP non-synthetic psilocybin extract for Psyence's initiatives.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:36 am

Psyence Biomed Ltd. (NASDAQ:PBM) has entered into a $25 million common stock purchase agreement with White Lion Capital, allowing the company to sell up to $25 million in shares over 24 months, subject to SEC conditions.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:57 pm

Edwards Lifesciences Corporation (NYSE:EW) shares fell sharply after reporting worse-than-expected Q2 sales and issuing weak Q3 guidance. Despite beating EPS estimates, the stock dipped 26.9%. The company also acquired JenaValve and Endotronix. Other notable movers include Predictive Oncology Inc. (NASDAQ:POAI), Psyence Biomedical Ltd. (NASDAQ:PBM), and Ford Motor Company (NYSE:F).

Portfolio Pulse from Avi Kapoor

July 25, 2024 | 6:12 pm

Psyence Biomedical Ltd (NASDAQ:PBM) shares surged by 48% to $0.58 after announcing the export of nature-derived psilocybin to Australia and the imminent start of a clinical trial. The trial will involve 84 patients and compare different doses of psilocybin with a placebo alongside psychotherapy.

Portfolio Pulse from Henry Khederian

July 25, 2024 | 5:24 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 1%. American Airlines cut its 2024 EPS outlook after reporting mixed Q2 results. Predictive Oncology, Psyence Biomedical, and Viking Therapeutics saw significant stock gains, while 2U, Edwards Lifesciences, and Ford experienced notable declines.

Portfolio Pulse from Avi Kapoor

July 25, 2024 | 5:11 pm

U.S. stocks traded mixed with the Dow Jones gaining over 200 points. Honeywell International Inc. reported strong Q2 results but lowered its FY24 EPS guidance. Predictive Oncology Inc., Psyence Biomedical Ltd., and Salarius Pharmaceuticals, Inc. saw significant stock price increases, while 2U, Inc., EZFill Holdings Inc., and Kindly MD, Inc. experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 25, 2024 | 2:39 pm

Psyence Biomedical shares have resumed trading after a temporary halt. The company is expected to make significant announcements that could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 1:40 pm

Psyence Biomedical shares have been halted to the downside despite the stock currently being up by 135.05%.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 1:35 pm

Indivior PLC (NASDAQ:INDV) shares surged 14.5% in pre-market trading after reporting better-than-expected Q2 earnings and announcing a $100 million share repurchase program. Other notable pre-market movers include Psyence Biomedical Ltd. (NASDAQ:PBM), BloomZ Inc. (NASDAQ:BLMZ), and 2U, Inc. (NASDAQ:TWOU), among others.

Portfolio Pulse from Avi Kapoor

July 25, 2024 | 10:36 am

Psyence Biomedical shares are trading higher after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:41 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.